Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Bova Score for Pulmonary Embolism Complications

    Predicts 30-day risk of PE-related complications.
    Favorite

    INSTRUCTIONS

    Use ONLY in hemodynamically stable patients (sBP ≥90) with confirmed acute PE (pulmonary embolism).

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with confirmed acute PE, defined as:

    • Intraluminal filling defect on PE protocol spiral CT, or
    • Positive V/Q scan, or
    • Normal or inconclusive CT or V/Q scan and positive lower extremity ultrasound.

    Do not use in hemodynamically unstable patients (sBP <90 mmHg).

    • The Bova Score risk stratifies normotensive patients with confirmed PE to identify patients at intermediate and high risk for complications and mortality associated with PE.
    • Use only in patients who are hemodynamically stable (sBP ≥90 mmHg).
    • Accounts for right ventricular dysfunction and cardiac biomarkers, unlike other scoring systems for PE.
    • Differs from the PESI (and sPESI), which were specifically designed to identify patients at low risk for mortality.
    • Use variables obtained at the time of diagnosis of acute PE.
    • Requires troponin and transthoracic echocardiography (TTE) or CT scan to assess for right ventricular dysfunction.
    • In normotensive patients, identifying those at high risk for PE-related events can be challenging.
    • The European Society of Cardiology recommends stratifying patients with PE in a stepwise approach using right ventricular dysfunction and cardiac biomarkers as part of the risk assessment. The Bova Score looks at both right ventricular dysfunction and cardiac biomarkers.  
    • Other clinical models (e.g. sPESI, Hestia Criteria) identify low-risk patients who may be candidates for outpatient therapy, but may not identify well-appearing patients who are at high risk and may benefit from escalated care (e.g. thrombolysis, ICU management).
    • May identify intermediate low and intermediate high (previously submassive) risk PE patients who benefit from advanced therapy.
    About the Creator
    Dr. Carlo Bova
    Content Contributors

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • Risk of PE-related complications (death from PE, hemodynamic collapse, or recurrent nonfatal PE) increases in patients with higher Bova Score.
    • Consider assessing high-risk patients for advanced therapy in addition to anticoagulation (catheter-directed therapy, thrombolytic therapy, IVC filter placement) if warranted.
    • Consider monitoring patients with intermediate and high risk Bova Scores in a higher level of care (stepdown unit, ICU).
    • Consider standard treatment (anticoagulation alone) for patients with a low risk Bova Score.

    Management

    • Optimal management of intermediate risk patients with acute PE is unclear, but escalation of care (e.g. thrombolysis, referral to ICU) should be considered in patients who are not low risk.
    • Consider multidisciplinary discussion regarding treatment options for patients with a high risk (>4) Bova Score.

    Critical Actions

    • High risk patients (stage III) should be monitored closely and a plan for rescue therapy should be made in case of clinical deterioration.
    • Stage III patients may warrant multidisciplinary discussion regarding management.
    • Additional findings and pathology not included in the Bova Score should also be considered, such as respiratory rate, need for respiratory support, SpO₂, syncope, elevated lactic acid, coexisting DVT, and other underlying chronic comorbidities.
    • The Bova Score does not predict risks of therapy such as bleeding with thrombolytic therapy or anticoagulation.

    Formula

    Addition of the selected points:

     

    0 points

    1 point

    2 points

    Systolic BP

    >100 mm Hg

    --

    90-100 mmHg

    Elevated cardiac troponin*

    No

    --

    Yes

    RV dysfunction**

    No

    --

    Yes

    Heart rate, beats/min

    <110

    ≥110

    --

    *Based on standard manufacturer assays and cutoff values.

    **On TTE: Right to left ventricular (RV/LV) ratio >0.9, systolic pulmonary artery pressure (sPAP) >30, RV end diastolic diameter >30mm, RV dilation, or free wall hypokinesis. On CT: RV/LV ratio >1 based on short axis diameter measurements.

    Facts & Figures

    Interpretation:

    Bova Score

    Stage

    PE-related complications*

    PE-related mortality

    0–2

    I (Low risk)

    4.4%

    3.1%

    3–4

    II (Intermediate risk)

    18%

    6.8%

    >4

    III (High risk)

    42%

    10%

    *Defined as a composite including death from PE, hemodynamic collapse, or recurrent nonfatal PE. Hemodynamic collapse = systolic BP <90 mm Hg for at least 15 min or need for catecholamines, thrombolysis, endotracheal intubation, or CPR.

    Evidence Appraisal

    The Bova Score was derived from a meta-analysis of six studies (2,874 patients) that comprised normotensive patients (sBP >90 mmHg) with an objectively confirmed diagnosis of acute PE who received standard anticoagulation alone. The study excluded patients who were hemodynamically unstable or received thrombolytic therapy at the time of diagnosis.

    Investigators identified predictors of PE-related complications in the patients studied and used them (systolic blood pressure, heart rate, troponin, right ventricular dysfunction) to build a model to estimate risk of PE-related complications. The PE-related complications considered were: death from PE, hemodynamic collapse, and recurrent non-fatal PE through 30 days after the diagnosis of PE.

    Right ventricular dysfunction was defined by TTE as any of the following:

    • Right to left ventricular (RV/LV) ratio >0.9.
    • Systolic pulmonary artery pressure (sPAP) >30.
    • RV end diastolic diameter >30mm.
    • RV dilation.
    • Free wall hypokinesis.

    Right ventricular dysfunction was defined by CT as RV/LV ratio >1 based on short axis diameter measurements. Elevated troponin was defined by positive value based on standard manufacturer assays and cutoff values.

    The Bova model was internally validated and performed fairly (AUROC 0.73, 95% CI 0.68–0.77) to predict PE-related complications in normotensive patients with confirmed PE.

    The investigators performed a subsequent study to externally validate the Bova Score in 1,083 normotensive patients with proven PE. In this study, the Bova Score performed similarly in predicting PE-related complications (AUROC 0.74, 95% CI 0.68-0.80).

    Dr. Carlo Bova

    About the Creator

    Carlo Bova, MD, is an internal medicine physician at Annunziata General Hospital in Cosenza, Italy. He is also one of the investigators of the PESIT (Prevalence of Pulmonary Embolism Among Patients Hospitalized for Syncope) study. Dr. Bova's research interest is in venous thromboembolism, and he has published several papers in this field.

    To view Dr. Carlo Bova's publications, visit PubMed

    Content Contributors